» Articles » PMID: 33999838

A Machine Learning Approach for Mortality Prediction in COVID-19 Pneumonia: Development and Evaluation of the Piacenza Score

Abstract

Background: Several models have been developed to predict mortality in patients with COVID-19 pneumonia, but only a few have demonstrated enough discriminatory capacity. Machine learning algorithms represent a novel approach for the data-driven prediction of clinical outcomes with advantages over statistical modeling.

Objective: We aimed to develop a machine learning-based score-the Piacenza score-for 30-day mortality prediction in patients with COVID-19 pneumonia.

Methods: The study comprised 852 patients with COVID-19 pneumonia, admitted to the Guglielmo da Saliceto Hospital in Italy from February to November 2020. Patients' medical history, demographics, and clinical data were collected using an electronic health record. The overall patient data set was randomly split into derivation and test cohorts. The score was obtained through the naïve Bayes classifier and externally validated on 86 patients admitted to Centro Cardiologico Monzino (Italy) in February 2020. Using a forward-search algorithm, 6 features were identified: age, mean corpuscular hemoglobin concentration, PaO/FiO ratio, temperature, previous stroke, and gender. The Brier index was used to evaluate the ability of the machine learning model to stratify and predict the observed outcomes. A user-friendly website was designed and developed to enable fast and easy use of the tool by physicians. Regarding the customization properties of the Piacenza score, we added a tailored version of the algorithm to the website, which enables an optimized computation of the mortality risk score for a patient when some of the variables used by the Piacenza score are not available. In this case, the naïve Bayes classifier is retrained over the same derivation cohort but using a different set of patient characteristics. We also compared the Piacenza score with the 4C score and with a naïve Bayes algorithm with 14 features chosen a priori.

Results: The Piacenza score exhibited an area under the receiver operating characteristic curve (AUC) of 0.78 (95% CI 0.74-0.84, Brier score=0.19) in the internal validation cohort and 0.79 (95% CI 0.68-0.89, Brier score=0.16) in the external validation cohort, showing a comparable accuracy with respect to the 4C score and to the naïve Bayes model with a priori chosen features; this achieved an AUC of 0.78 (95% CI 0.73-0.83, Brier score=0.26) and 0.80 (95% CI 0.75-0.86, Brier score=0.17), respectively.

Conclusions: Our findings demonstrated that a customizable machine learning-based score with a purely data-driven selection of features is feasible and effective for the prediction of mortality among patients with COVID-19 pneumonia.

Citing Articles

Surfactant-derived protein type B: a new biomarker linked to respiratory failure and lung damage in mild to moderate SARS-CoV-2 pneumonia.

Mapelli M, Salvioni E, Mattavelli I, Banfi C, Ghilardi S, Greco A ERJ Open Res. 2024; 10(6).

PMID: 39588076 PMC: 11587118. DOI: 10.1183/23120541.00301-2024.


Assessment of Sepsis Risk at Admission to the Emergency Department: Clinical Interpretable Prediction Model.

Aygun U, Yagin F, Yagin B, Yasar S, Colak C, Ozkan A Diagnostics (Basel). 2024; 14(5).

PMID: 38472930 PMC: 10931325. DOI: 10.3390/diagnostics14050457.


Effects of the pre-existing coronary heart disease on the prognosis of COVID-19 patients: A systematic review and meta-analysis.

Wang S, Zhu R, Zhang C, Guo Y, Lv M, Zhang C PLoS One. 2023; 18(10):e0292021.

PMID: 37815980 PMC: 10564240. DOI: 10.1371/journal.pone.0292021.


Machine learning-based mortality prediction models for smoker COVID-19 patients.

Sharifi-Kia A, Nahvijou A, Sheikhtaheri A BMC Med Inform Decis Mak. 2023; 23(1):129.

PMID: 37479990 PMC: 10360290. DOI: 10.1186/s12911-023-02237-w.


Artificial intelligence-driven prediction of COVID-19-related hospitalization and death: a systematic review.

Shakibfar S, Nyberg F, Li H, Zhao J, Nordeng H, Sandve G Front Public Health. 2023; 11:1183725.

PMID: 37408750 PMC: 10319067. DOI: 10.3389/fpubh.2023.1183725.


References
1.
Wiersinga W, Rhodes A, Cheng A, Peacock S, Prescott H . Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020; 324(8):782-793. DOI: 10.1001/jama.2020.12839. View

2.
Lippi G, Plebani M . Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 2020; 58(7):1131-1134. DOI: 10.1515/cclm-2020-0198. View

3.
DAscenzo F, De Filippo O, Gallone G, Mittone G, Deriu M, Iannaccone M . Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets. Lancet. 2021; 397(10270):199-207. DOI: 10.1016/S0140-6736(20)32519-8. View

4.
Estiri H, Strasser Z, Klann J, Naseri P, Wagholikar K, Murphy S . Predicting COVID-19 mortality with electronic medical records. NPJ Digit Med. 2021; 4(1):15. PMC: 7862405. DOI: 10.1038/s41746-021-00383-x. View

5.
Biagi A, Rossi L, Malagoli A, Zanni A, Sticozzi C, Comastri G . Clinical and epidemiological characteristics of 320 deceased patients with COVID-19 in an Italian Province: A retrospective observational study. J Med Virol. 2020; 92(11):2718-2724. PMC: 7300458. DOI: 10.1002/jmv.26147. View